Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Melanoma 2Lymphoma, T-Cell, Peripheral 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 155Dexamethasone 141Rituximab 85fludarabine 80Lenalidomide 72Cytarabine 70Bortezomib 65fludarabine phosphate 63Gemcitabine 62venetoclax 55pomalidomide 53Etoposide 53pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × HBI-8000 × Clear all
NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Great Novel Therapeutics Biotech & Medicals Corporation

Phase 2 Recruiting
33 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡